Azaindazole compounds and methods of use
US9296740B2 · kind B2 · utility
0Cited by
15References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2013 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Feb 22, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.